Active Biotech regains rights of laquinimod from Teva
EuroBiotech Report—Teva dumps laquinimod, Gilead-Galapagos, GV-Evox, Abivax data and ProQR | Fierce Biotech
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review | SpringerLink
Laquinimod - an overview | ScienceDirect Topics
Teva drops development of laquinimod - PharmaTimes
A Broad Look At Teva's Pipeline (NYSE:TEVA) | Seeking Alpha
Roquinimex - wikidoc
laquinimod
Teva hit with largest-ever fine under US anti-corruption act - PMLiVE
Laquinimod | C19H17ClN2O3 | CID 54677946 - PubChem
Patient enrollment in Phase III trial of laquinimod completed
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis | NEJM
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Is Teva doomed after Copaxone's increased competition and Laquinimod's failed Phase III trial? - Pharmaceutical Technology
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Laquinimod - an overview | ScienceDirect Topics
Molecules | Free Full-Text | Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
AhR activators - friend or foe? - Hypha Discovery Blogs
PDF) Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity
Active Biotech and Teva together in a Phase II clinical trial against Huntington's disease - Labiotech.eu
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
AhR activators - friend or foe? - Hypha Discovery Blogs
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
